IDEXX Laboratories Inc
NASDAQ:IDXX

Watchlist Manager
IDEXX Laboratories Inc Logo
IDEXX Laboratories Inc
NASDAQ:IDXX
Watchlist
Price: 417.24 USD -0.31% Market Closed
Market Cap: 34.2B USD
Have any thoughts about
IDEXX Laboratories Inc?
Write Note

Net Margin
IDEXX Laboratories Inc

22.5%
Current
22%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
22.5%
=
Net Income
866.2m
/
Revenue
3.8B

Net Margin Across Competitors

Country US
Market Cap 34.3B USD
Net Margin
23%
Country US
Market Cap 204.9B USD
Net Margin
14%
Country US
Market Cap 195.2B USD
Net Margin
29%
Country US
Market Cap 146.7B USD
Net Margin
16%
Country US
Market Cap 132.6B USD
Net Margin
11%
Country IE
Market Cap 110.6B USD
Net Margin
12%
Country US
Market Cap 64.7B USD
Net Margin
9%
Country DE
Market Cap 55.6B EUR
Net Margin
8%
Country CN
Market Cap 319.2B CNY
Net Margin
34%
Country US
Market Cap 41.6B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

IDEXX Laboratories Inc
Glance View

Market Cap
34.3B USD
Industry
Health Care

IDEXX Laboratories Inc. is a leading global provider of veterinary diagnostic products and services, dedicated to enhancing the health and well-being of pets worldwide. Founded in 1983, the company has established itself as an innovator in the animal healthcare market, offering a comprehensive range of diagnostic tests, equipment, and software that empower veterinarians to make informed decisions. With a consistent focus on research and development, IDEXX has expanded its portfolio to include cutting-edge solutions such as digital imaging and telemedicine, addressing the growing needs of the pet care industry. Their strategic partnerships and robust distribution channels further bolster their presence in both developed and emerging markets. For investors, IDEXX represents a compelling opportunity within a steadily growing sector. The company's recurring revenue model, driven by its suite of diagnostic tests and subscriptions to software solutions, ensures stable cash flow and predictability in earnings. IDEXX has also demonstrated impressive financial performance, characterized by strong revenue growth, high profit margins, and a commitment to shareholder returns. By harnessing trends in pet ownership and increasing expenditures on pet healthcare, IDEXX positions itself as a reliable player in the marketplace. With its dedication to innovation, customer service, and global expansion, IDEXX Laboratories Inc. stands poised for sustained growth, making it an attractive consideration for long-term investors.

IDXX Intrinsic Value
253.04 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
22.5%
=
Net Income
866.2m
/
Revenue
3.8B
What is the Net Margin of IDEXX Laboratories Inc?

Based on IDEXX Laboratories Inc's most recent financial statements, the company has Net Margin of 22.5%.